Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Adagrasib→

Adagrasib Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
2326521-71-3
Molecular formula
C32H35ClFN7O2
Molecular weight
604.1 g/mol
Drug class
Targeted antineoplasticirreversible KRAS G12C inhibitor
Mechanism of action
Irreversibly and covalently binds the mutant cysteine in KRAS G12C, locking the mutant protein in its inactive state and preventing downstream signalling without inhibiting wild-type KRAS.
Indications / reported uses
  • As monotherapy for adults with KRAS G12C-mutated locally advanced or metastatic non-small-cell lung cancer after at least one prior systemic therapy (accelerated approval; continued approval may depend on confirmatory evidence)
  • In combination with cetuximab for adults with KRAS G12C-mutated locally advanced or metastatic colorectal cancer after prior fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy

Sources: NLM DailyMed — KRAZATI (adagrasib), updated 31 Aug 2026 · US FDA prescribing information · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Adagrasib Environmental Risk Assessment (ERA) (the Adagrasib ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.